With standout facilities and strong industry links, the School prepares students for careers in health and medical science.
Excludes commercial-in-confidence projects.
Research since 2008 is shown below.
Open access indicates that an output is open access.
Sweetman, MJ, Sebben, D, Noll, BD, Wang, WH, May, S, Mebberson, N, Plush, SE & Hayball, JD 2018, 'A rapid technique to determine performance and efficiency of activated carbon water filters', Water science and technology: water supply, vol. 18, no. 2, pp. 371-382.
Diab, S, Abdelaziz, AM, Li, P, Teo, T, Basnet, SK, Noll, B, Rahaman, MH, Lu, J, Hou, J, Yu, M, Le, BT, Albrecht, H, Milne, RW & Wang, S 2017, 'Dual inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia', European journal of medicinal chemistry, vol. 24, no. 6, pp. 575-591.
O'Brien-Brown, J, Jackson, A, Reekie, TA, Barron, ML, Werry, EL, Schiavini, P, McDonnell, M, Munoz, L, Wilkinson, S, Noll, B, Wang, S & Kassiou, M 2017, 'Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists', European journal of medicinal chemistry, vol. 130, pp. 433-439.
5 4 3
Tadesse, S, Bantie, L, Tomusange, K, Yu, M, Islam, S, Bykovska, N, Noll, B, Zhu, G, Li, P, Lam, F, Kumarasiri, M, Milne, R & Wang, S 2017, 'Discovery and pharmacological characterisation of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents', British journal of pharmacology, online, pp. 1-32.
Zeleke, S, Yu, M, Mekonnen, LB, Lam, F, Islam, S, Tomusange, K, Rahaman, MH, Noll, B, MC Basnet, S, Teo, T, Albrecht, H, Milne, R & Wang, S 2017, 'Highly potent, selective, and orally bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation', Journal of medicinal chemistry, vol. 60, no. 5, pp. 1892-1915.
Open access 5 2
Sutton, SK, Carter, DR, Kim, P, Tan, O, Arndt, GM, Zhang, XD, Baell, J, Noll, BD, Wang, S, Kumar, N, McArthur, GA, Cheung, BB & Marshall, GM 2016, 'A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner', Oncotarget, vol. 7, no. 32, pp. 52166-52178.
Open access 1
External engagement & recognition
|Peter MacCallum Cancer Centre||AUSTRALIA|
|Puratap Pty Ltd||AUSTRALIA|
|Sydney Children's Hospital||AUSTRALIA|
|University of New South Wales||AUSTRALIA|
|University of Newcastle||AUSTRALIA|
|University of South Australia||AUSTRALIA|
|University of Sydney||AUSTRALIA|
|Zhejiang Gongshang University||CHINA|